Shaping the future of animal health
Virbac group

A company dedicated
to animal health

Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Ranked 8th worldwide and present in more than 100 countries, the company offers a comprehensive range of products and services intended for veterinarians, farmers and animal owners.

Corporate news

Feb 20 - VDS: Virbac's commitment to the dairy sector

At the beginning of October the GMBO (Global Marketing) organized the first Virbac Dairy Symposium in France, attended by experts from the dairy sector and Virbac staff from all over the world. Fabrice Payot, Global Marketing manager on the dairy cattle segment, explains the objectives of this major event.   

Jan 09 - St. Louis: to better serve product innovation

Virbac United States inaugurates the April 20th, 2014 a new building for its R&D activities. With which objectives? The answers from R&D vice-president of the American subsidiary.

Dec 15 - Development of new monoclonal antibody-based veterinary medicines: Virbac announces the signature of a collaboration agreement with Nexvet

As the world's 5th largest manufacturer in the companion animal market, a major part of Virbac's Research & Development investment is made in this field. In this context, the Group is pleased to announce the signature of a ten-year collaboration agreement with biopharmaceutical company Nexvet. The aim of this agreement is for Virbac to provide input to Nexvet’s development of new monoclonal antibody-based veterinary medicines and to market these medicines, if approved by regulators, outside the USA and Canada.  

Join Virbac

Career opportunities, company values, testimonials... Discover our career section.

Customer driven innovation

To meet the customers' essential needs, in almost all the therapeutic segments and for nearly all species. Such is the philosophy of Virbac innovation. For this purpose, the company develops...

Financial public releases

Jan 15 - 2014 Annual consolidated sales

  Sustained growth in the fourth quarter

Jan 05 - Virbac announces the closing of the SENTINEL® brands family acquisition in the United States

Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® Flavor Tabs® and SENTINEL® SPECTRUM®, marketed up to now by Novartis Animal Health.

Oct 27 - Virbac agrees to acquire veterinary assets from Eli Lilly in the United States

Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.

Corporate responsibility

Company culture, economic and social responsibility, citizenship, environment... From its very beginning, forty years ago, Virbac has taken a long-term view.